Advertisement

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Advertisement

Advertisement




Sep
10
Today In Oncology
NSCLC FDA Grants Accelerated Approval to Sevabertinib for Locally Advanced or Metastatic Nonsquamous Disease
Refined Risk Index Improves Outcome Prediction After Limited-Duration CLL Therapy
SUO/AUA Updates Guidelines for Non-Muscle Invasive Bladder Cancer
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
Early ctDNA Molecular Response May Predict Outcomes With Azenosertib in Ovarian Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo